Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Риск развития внебольничной пневмонии у пациентов с сахарным диабетом - Журнал Терапевтический архив №3 Вопросы пульмонологии 2022
Риск развития внебольничной пневмонии у пациентов с сахарным диабетом
Игнатова Г.Л., Блинова Е.В., Струч С.В., Сырочкина М.А. Риск развития внебольничной пневмонии у пациентов с сахарным диабетом. Терапевтический архив. 2022;94(3):448–453.
DOI: 10.26442/00403660.2022.03.201447
DOI: 10.26442/00403660.2022.03.201447
DOI: 10.26442/00403660.2022.03.201447
________________________________________________
DOI: 10.26442/00403660.2022.03.201447
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье впервые приведен достаточно полный обзор основных аспектов эпидемиологии и клинических особенностей инфекционной патологии, в частности внебольничных пневмоний, как коморбидных и отягощающих состояний у пациентов с сахарным диабетом 1 и 2-го типов. Рассмотрены факторы риска и патогенетические паттерны развития инфекционных процессов, а также особая этиологическая роль пневмококковой инфекции в данной группе пациентов. Особое внимание уделено возможностям и подходам к первичной профилактике вакциноуправляемых инфекций как причин развития внебольничных пневмоний и инвазивных заболеваний у больных сахарным диабетом с обзором международных исследований, рекомендаций и отечественного опыта по иммунизации против пневмококковой инфекции.
Ключевые слова: сахарный диабет, внебольничные пневмонии, пневмококковая инфекция, вакцинация
Keywords: diabetes mellitus, community-acquired pneumonia, pneumococcal infection, vaccination
Ключевые слова: сахарный диабет, внебольничные пневмонии, пневмококковая инфекция, вакцинация
________________________________________________
Keywords: diabetes mellitus, community-acquired pneumonia, pneumococcal infection, vaccination
Полный текст
Список литературы
1. Российское респираторное общество. Межрегиональная ассоциация по клинической микробиологии и антимикробной химиотерапии. Клинические рекомендации: Внебольничная пневмония у взрослых. М., 2021 [Rossiiskoe respiratornoe obshchestvo. Mezhregional'naia assotsiatsiia po klinicheskoi mikrobiologii i antimikrobnoi khimioterapii. Klinicheskie rekomendatsii: Vnebol'nichnaia pnevmoniia u vzroslykh. Moscow, 2021 (in Russian)].
2. Wroe PC, Finkelstein JA, Ray GT, et al. Aging population and future burden of pneumococcal pneumonia in the United States. J Infect Dis. 2012;205(10):1589-92. DOI:10.1093/infdis/jis240
3. Заболеваемость взрослого населения России в 2019 году с диагнозом, установленным впервые в жизни. Статистические материалы. М., 2020 [Zabolevaemost' vzroslogo naseleniia Rossii v 2019 godu s diagnozom, ustanovlennym vpervye v zhizni. Statisticheskie materialy. Moscow, 2020 (in Russian)].
4. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquiredpneumonia among adults in Europe. Thorax. 2012;67:71-9. DOI:10.1136/thx.2009.129502
5. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39(11):1642-50. DOI:10.1086/425615
6. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122(2):130-41. DOI:10.3810/pgm.2010.03.2130
7. Ramirez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clin Infect Dis. 2017;65(11):1806-12. DOI:10.1093/cid/cix647
8. World Health Organization. The top 10 causes of death: 2019 updated. Available at: https://www.who.int/ru/news/item/09-12-2020-who-reveals-leading-causes-of-death-and-disability-world.... Accessed: 09.12.2020.
9. Metlay JP, Fine MJ. Testing strategies in the initial management of patents with community-acquired pneumonia. Ann Intern Med. 2003;138(2):109-18.
DOI:10.7326/0003-4819-138-2-200301210-00012
10. International Diabetes Federation. Diabetes Atlas 9th Ed. 2019. Available at: https://www.diabetesatlas.org/upload/resources/material/ Accessed: 09.12.2020.
11. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 10-й вып. М., 2021 [Algorithms of specialized medical care for patients with diabetes mellitus. Ed. II Dedov, MV Shestakova, A.Yu. Maiorov. 10th ed. Moscow, 2021 (in Russian)].
DOI:10.14341/DM12802
12. Дедов И.И., Калашникова М.Ф., Белоусов Д.Ю., и др.Фармакоэпидемиологические аспекты мониторинга здоровья пациентов с сахарным диабетом 2 типа: результаты Российского наблюдательного многоцентрового эпидемиологического исследования ФОРСАЙТ-СД 2. Сахарный диабет. 2016;19(6):443-56 [Dedov II, Kalashnikova MF, Belousov DY, et al. Assessing routine healthcare pattern for type 2 diabetes mellitus in Russia: the results of рharmacoepidemiological study (FORSIGHT-DM2). Diabetes Mellitus. 2016;19(6):443-56 (in Russian)]. DOI:10.14341/DM8146
13. Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infections disease hospitalization and outcome. Diabetologia. 2007;50(3):549-54. DOI:10.1007/s00125-006-0570-3
14. Kornum JB, Thomsen RW, Riis A, et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008;31(8):1541-5. DOI:10.2337/dc08-0138
15. Bruns AH, Oesterheert JJ, Cucciolillo MC, et al. Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia as compared with the general Dutch population. Clin Microbiol Infect. 2011;17(5):763-8. DOI:10.1111/j.1469-0691.2010.03296.x
16. Lepper HM, Ott S, Nuesch E, et al. German Community Acquired Pneumonia Competence Network. Serum glucose level for predicting death in patients admitted to hospital for community-acquired pneumonia: prospective cohort study. BMJ. 2012;344(5):3397. DOI:10.1136/bmj.e3397
17. Kondapally Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk cause-specific death. The emerging risk factors collaboration. N Engl J Med. 2011;364(9):829-41. DOI:10.1056/NEJMoa1008862
18. Жук Е.А. Изменения иммунологических параметров при диабетическом кетоацидозе. Актуальные проблемы современной эндокринологии: Материалы IV Всероссийского конгресса эндокринологов. СПб., 2001; с. 68 [Zhuk EA. Izmeneniia immunologicheskikh parametrov pri diabeticheskom ketoatsidoze. Aktual'nye problemy sovremennoi endokrinologii: Materialy IV Vserossiiskogo kongressa endokrinologov. Saint Petersburg, 2001; p. 68 (in Russian)].
19. Костинов М.П., Тарасова А.А. Вакцинопрофилактика пневмококковой инфекции и гриппа при аутоиммунных заболеваниях. Руководство для врачей. М.: МДВ, 2009 [Kostinov MP, Tarasova AA. Vaktsinoprofilaktika pnevmokokkovoi infektsii i grippa pri autoimmunnykh zabolevaniiakh. Rukovodstvo dlia vrachei. Moscow: MDV, 2009 (in Russian)].
20. Clement S, Braithwaite SS, Magel MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27(2):553-91. DOI:10.2337/diacare.27.2.553
21. Verrotti A, Loiacono G, Mohn A, et al. New in sights in diabetic autonomic neuropathy in children and adolescents. Eur J Endocrinol. 2009;161:811-8.
DOI:10.1530/EJE-09-0710
22. Лысенко Л.В. Диабетическая макро- и микроангиопатия легких. Арх. патогии. 1990;11:31-6 [Lysenko LV. Diabetic macro- and microangiopathy of the lungs. Arch. patologii. 1990;11:31-6 (in Russian)].
23. Колодова И.М., Лысенко Л.В., Салтыков Б.Б. Изменения в легких при сахарном диабете. Арх. патологии. 1982;7:35-40 [Kolodova IM, Lysenko LV, Saltykov B. Changes in the lungs in diabetes mellitus. Arch. patologii. 1982;7:35-40 (in Russian)].
24. Movahed MR, Hashemzadeh M, Jamal MM. The prevalence of pulmonary embolism and pulmonary hypertension in patients with type II diabetes mellitus. CHEST. 128(5):3568-71. DOI:10.1378/chest.128.5.3568
25. Zhang RH, Zhou JB, Cai YM, et al. Non-linear association between diabetes mellitus and pulmonary function: a population-based study. Respir Res. 2020;21(1):292. DOI:10.1186/s12931-020-01538-2
26. Lange P, Groth S, Kastrup J, et al. Diabetes mellitus, plasma glucose and lung function in a cross-sectional population study. Eur Resp. 1989;2:4-19.
27. Mancini M, Filippelli G, Seghieri, et al. Respiratory muscle function and hypoxic ventilatory control in patients with type I diabetes. Chest. 1999;115(6):1553-62. DOI:10.1378/chest.115.6.1553
28. Benbassat CA, Stern E, Kramer M, et al. Pulmonary function in patients with diabetes mellitus. Am J Med Sci. 2001;322(3):127-32. DOI:10.1097/00000441-200109000-00003
29. Boulbou MS, Gourgoulianis KI, Klisiaris VV, et al. Diabetes mellitus and lung function. Med Princ Pract. 2003;12(2):87-91. DOI:10.1159/000069118
30. Муминоров А.И., Шамирзоев Н.Х., Джаббаров Н.Д. Морфологические исследования слизистой оболочки носовой полости при сахарном диабете. Вестн. отоларингологии. 1980;4:39-42 [Muminorov AI, Shamirzoev NKh, Jabbarov ND. Morphological studies of the nasal mucosa in diabetes mellitus. Vestn. otolaryngologii. 1980;4:39-42 (in Russian)].
31. Yue W. Nasal mucocillary clearance in patients with diabetes mellitus. J Laryngol Otol. 1989;103(9):853-5. DOI:10.1017/s0022215100110291
32. Sachdeva A, Sachdeva O, Gualti S, еt al. Nasal mucocilliary clearance & mucus pH in patients with diabetes mellitus. Indian J Med Res. 1993;98:265-68.
33. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):ofu024. DOI:10.1093/ofid/ofu024
34. Иванчик Н.В., Чагарян А.Н., Сухорукова М.В., и др. Антибиотико-резистентность клинических штаммов Streptococcus pneumoniae в России: результаты многоцентрового эпидемиологического исследования «ПЕГАС 2014–2017». Клиническая микробиология и антимикробная химиотерапия. 2019;21(3):230-7 [Ivanchik NV, Chagaryan АN, Sukhorukova МV, et al. Antimicrobial resistance of clinical Streptococcus pneumoniae isolates in Russia: the results of multicenter epidemiological study “PEHASus 2014–2017”. Clinical Microbiology and Antimicrobial Chemotherapy. 2019;21(3):230-7 (in Russian)]. DOI:10.36488/cmac.2019.3.230-237
35. Белошитский Г.В., Королева И.С., Миронов К.О. Фенотипическая и генотипическая характеристика штаммов пневмококков, выделенных от больных пневмококковым менингитом. Клиническая микробиология и антимикробная химиотерапия. 2011;13(3):216-66
[Beloshitsky GV, Koroleva IS, Mironov KO. Phenotypic and genotypic characteristics of pneumococcal strains isolated from patients with pneumococcal meningitis. Clinical Microbiology and Antimicrobial Chemotherapy. 2011;13(3):216-66 (in Russian)].
36. Pollard AJ, Bijker EM. A guide to vaccinology: from basicprinciples to new developments. Nat Rev Immunol. 2021;21(2):83-100. DOI:10.1038/s41577-020-00479-7
37. Руководство по клинической иммунологии в респираторной медицине. Под ред М.П. Костинова, А.Г. Чучалина. М., 2018 [Rukovodstvo po klinicheskoi immunologii v respiratornoi meditsine. Pod red. MP Kostinova, AG Chuchalina. Moscow, 2018 (in Russian)].
38. Чучалин А.Г., Брико Н.И., Авдеев С.Н., и др. Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у взрослых. Пульмонология. 2019;29(1):19-34 [Chuchalin AG, Briko NI, Avdeev SN, et al. Federal Clinical Guidelines on Preventive Vaccination Against Pneumococcal infections in Adults. Pulmonologiya. 2019;29(1):19-34 (in Russian)]. DOI:10.18093/0869-0189-2019-29-1-19-34
39. Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60–64 years of age. Vaccine. 2014;32(20):2364-74. DOI:10.1016/j.vaccine.2014.02.002
40. Shiramoto M, Hanada R, Juergens C, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. Hum Vaccin Immunother. 2015;11(9):2198-206. DOI:10.1080/21645515.2015.1030550
41. Kuo CS, Lu CW, Chang YK, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly. Medicine (Baltimore). 2016;95(26):e4064. DOI:10.1097/MD.0000000000004064
42. McDonald HI, Thomas SL, Millett ER, et al. Do influenza and pneumococcal vaccines prevent community-acquired respiratory infections among older people with diabetes and does this vary by chronic kidney disease? A cohort study using electronic health record. BMJ Open Diabetes Res Care. 2017;5:e000332. DOI:10.1136/bmjdrc-2016-000332
43. Bonten MJ, Huijts SM, Bolkenbaas V, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-25. DOI:10.1056/NEJMoa1408544
44. Huijts SM, van Werkhoven CH, Bolkenbaas M, et al. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly. Vaccine. 2017;35(34):4444-9. DOI:10.1016/j.vaccine.2017.01.071
45. McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. Clin Infect Dis. 2018;67(10):1498-506. DOI:10.1093/cid/ciy312
46. Ehrlich SF, Quesenberry CP Jr, Van Den Eeden SK, et al. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care. 2010;33(1):55-60. DOI:10.2337/dc09-0880
47. Wells CE, Baker EH. Metabolic syndrome and diabetes mellitus in COPD. Eur Respir Soc Monograph. 2013;59:117-34.
48. Игнатова Г.Л., Блинова Е.В., Антонов В.Н., и др. Анализ влияния вакцинопрофилактики пневмококковой инфекции у пациентов с хронической обструктивной болезнью легких в сочетании с сахарным диабетом. Терапевтический архив. 2019;91(11):49-54 [Ignatova GL, Blinova EV, Antonov VN, et al. Analysis of the effect of vaccine prevention of pneumococcal infection in patients with chronic obstructive pulmonary disease in combination with diabetes mellitus. TerapevticheskiiArkhiv (Ter. Arkh.). 2019;91(11):49-54 (in Russian)]. DOI:10.26442/00403660.2019.11.000424
49. Драпкина О.М., Брико Н.И., Костинов М.П., и др. Иммунизация взрослых. Методические рекомендации. М.: ФГБУ «НМИЦ ТПМ» Минздрава России, 2020. Режима доступа: http://nasci.ru/?id=19860&download=1 Ссылка активна на 11.02.2022 [Drapkina OM, Briko NI, Kostinov MP, et al. Immunization of adults. Guidelines. Moscow: NMITs TPM, 2020. Available at: http://nasci.ru/?id=19860&download=1. Accessed: 11.02.22 (in Russian)].
2. Wroe PC, Finkelstein JA, Ray GT, et al. Aging population and future burden of pneumococcal pneumonia in the United States. J Infect Dis. 2012;205(10):1589-92. DOI:10.1093/infdis/jis240
3. Zabolevaemost' vzroslogo naseleniia Rossii v 2019 godu s diagnozom, ustanovlennym vpervye v zhizni. Statisticheskie materialy. Moscow, 2020 (in Russian).
4. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquiredpneumonia among adults in Europe. Thorax. 2012;67:71-9. DOI:10.1136/thx.2009.129502
5. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39(11):1642-50. DOI:10.1086/425615
6. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122(2):130-41. DOI:10.3810/pgm.2010.03.2130
7. Ramirez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clin Infect Dis. 2017;65(11):1806-12. DOI:10.1093/cid/cix647
8. World Health Organization. The top 10 causes of death: 2019 updated. Available at: https://www.who.int/ru/news/item/09-12-2020-who-reveals-leading-causes-of-death-and-disability-world.... Accessed: 09.12.2020.
9. Metlay JP, Fine MJ. Testing strategies in the initial management of patents with community-acquired pneumonia. Ann Intern Med. 2003;138(2):109-18.
DOI:10.7326/0003-4819-138-2-200301210-00012
10. International Diabetes Federation. Diabetes Atlas 9th Ed. 2019. Available at: https://www.diabetesatlas.org/upload/resources/material/ Accessed: 09.12.2020.
11. Algorithms of specialized medical care for patients with diabetes mellitus. Ed. II Dedov, MV Shestakova, A.Yu. Maiorov. 10th ed. Moscow, 2021 (in Russian).
DOI:10.14341/DM12802
12. Dedov II, Kalashnikova MF, Belousov DY, et al. Assessing routine healthcare pattern for type 2 diabetes mellitus in Russia: the results of рharmacoepidemiological study (FORSIGHT-DM2). Diabetes Mellitus. 2016;19(6):443-56 (in Russian). DOI:10.14341/DM8146
13. Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infections disease hospitalization and outcome. Diabetologia. 2007;50(3):549-54. DOI:10.1007/s00125-006-0570-3
14. Kornum JB, Thomsen RW, Riis A, et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008;31(8):1541-5. DOI:10.2337/dc08-0138
15. Bruns AH, Oesterheert JJ, Cucciolillo MC, et al. Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia as compared with the general Dutch population. Clin Microbiol Infect. 2011;17(5):763-8. DOI:10.1111/j.1469-0691.2010.03296.x
16. Lepper HM, Ott S, Nuesch E, et al. German Community Acquired Pneumonia Competence Network. Serum glucose level for predicting death in patients admitted to hospital for community-acquired pneumonia: prospective cohort study. BMJ. 2012;344(5):3397. DOI:10.1136/bmj.e3397
17. Kondapally Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk cause-specific death. The emerging risk factors collaboration. N Engl J Med. 2011;364(9):829-41. DOI:10.1056/NEJMoa1008862
18. Zhuk EA. Izmeneniia immunologicheskikh parametrov pri diabeticheskom ketoatsidoze. Aktual'nye problemy sovremennoi endokrinologii: Materialy IV Vserossiiskogo kongressa endokrinologov. Saint Petersburg, 2001; p. 68 (in Russian).
19. Kostinov MP, Tarasova AA. Vaktsinoprofilaktika pnevmokokkovoi infektsii i grippa pri autoimmunnykh zabolevaniiakh. Rukovodstvo dlia vrachei. Moscow: MDV, 2009 (in Russian).
20. Clement S, Braithwaite SS, Magel MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27(2):553-91. DOI:10.2337/diacare.27.2.553
21. Verrotti A, Loiacono G, Mohn A, et al. New in sights in diabetic autonomic neuropathy in children and adolescents. Eur J Endocrinol. 2009;161:811-8.
DOI:10.1530/EJE-09-0710
22. Lysenko LV. Diabetic macro- and microangiopathy of the lungs. Arch. patologii. 1990;11:31-6 (in Russian).
23. Kolodova IM, Lysenko LV, Saltykov B. Changes in the lungs in diabetes mellitus. Arch. patologii. 1982;7:35-40 (in Russian).
24. Movahed MR, Hashemzadeh M, Jamal MM. The prevalence of pulmonary embolism and pulmonary hypertension in patients with type II diabetes mellitus. CHEST. 128(5):3568-71. DOI:10.1378/chest.128.5.3568
25. Zhang RH, Zhou JB, Cai YM, et al. Non-linear association between diabetes mellitus and pulmonary function: a population-based study. Respir Res. 2020;21(1):292. DOI:10.1186/s12931-020-01538-2
26. Lange P, Groth S, Kastrup J, et al. Diabetes mellitus, plasma glucose and lung function in a cross-sectional population study. Eur Resp. 1989;2:4-19.
27. Mancini M, Filippelli G, Seghieri, et al. Respiratory muscle function and hypoxic ventilatory control in patients with type I diabetes. Chest. 1999;115(6):1553-62. DOI:10.1378/chest.115.6.1553
28. Benbassat CA, Stern E, Kramer M, et al. Pulmonary function in patients with diabetes mellitus. Am J Med Sci. 2001;322(3):127-32. DOI:10.1097/00000441-200109000-00003
29. Boulbou MS, Gourgoulianis KI, Klisiaris VV, et al. Diabetes mellitus and lung function. Med Princ Pract. 2003;12(2):87-91. DOI:10.1159/000069118
30. Muminorov AI, Shamirzoev NKh, Jabbarov ND. Morphological studies of the nasal mucosa in diabetes mellitus. Vestn. otolaryngologii. 1980;4:39-42 (in Russian).
31. Yue W. Nasal mucocillary clearance in patients with diabetes mellitus. J Laryngol Otol. 1989;103(9):853-5. DOI:10.1017/s0022215100110291
32. Sachdeva A, Sachdeva O, Gualti S, еt al. Nasal mucocilliary clearance & mucus pH in patients with diabetes mellitus. Indian J Med Res. 1993;98:265-68.
33. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):ofu024. DOI:10.1093/ofid/ofu024
34. Ivanchik NV, Chagaryan АN, Sukhorukova МV, et al. Antimicrobial resistance of clinical Streptococcus pneumoniae isolates in Russia: the results of multicenter epidemiological study “PEHASus 2014–2017”. Clinical Microbiology and Antimicrobial Chemotherapy. 2019;21(3):230-7 (in Russian). DOI:10.36488/cmac.2019.3.230-237
35. Beloshitsky GV, Koroleva IS, Mironov KO. Phenotypic and genotypic characteristics of pneumococcal strains isolated from patients with pneumococcal meningitis. Clinical Microbiology and Antimicrobial Chemotherapy. 2011;13(3):216-66 (in Russian).
36. Pollard AJ, Bijker EM. A guide to vaccinology: from basicprinciples to new developments. Nat Rev Immunol. 2021;21(2):83-100. DOI:10.1038/s41577-020-00479-7
37. Rukovodstvo po klinicheskoi immunologii v respiratornoi meditsine. Pod red. MP Kostinova, AG Chuchalina. Moscow, 2018 (in Russian).
38. Chuchalin AG, Briko NI, Avdeev SN, et al. Federal Clinical Guidelines on Preventive Vaccination Against Pneumococcal infections in Adults. Pulmonologiya. 2019;29(1):19-34 (in Russian). DOI:10.18093/0869-0189-2019-29-1-19-34
39. Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60–64 years of age. Vaccine. 2014;32(20):2364-74. DOI:10.1016/j.vaccine.2014.02.002
40. Shiramoto M, Hanada R, Juergens C, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. Hum Vaccin Immunother. 2015;11(9):2198-206. DOI:10.1080/21645515.2015.1030550
41. Kuo CS, Lu CW, Chang YK, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly. Medicine (Baltimore). 2016;95(26):e4064. DOI:10.1097/MD.0000000000004064
42. McDonald HI, Thomas SL, Millett ER, et al. Do influenza and pneumococcal vaccines prevent community-acquired respiratory infections among older people with diabetes and does this vary by chronic kidney disease? A cohort study using electronic health record. BMJ Open Diabetes Res Care. 2017;5:e000332. DOI:10.1136/bmjdrc-2016-000332
43. Bonten MJ, Huijts SM, Bolkenbaas V, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-25. DOI:10.1056/NEJMoa1408544
44. Huijts SM, van Werkhoven CH, Bolkenbaas M, et al. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly. Vaccine. 2017;35(34):4444-9. DOI:10.1016/j.vaccine.2017.01.071
45. McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. Clin Infect Dis. 2018;67(10):1498-506. DOI:10.1093/cid/ciy312
46. Ehrlich SF, Quesenberry CP Jr, Van Den Eeden SK, et al. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care. 2010;33(1):55-60. DOI:10.2337/dc09-0880
47. Wells CE, Baker EH. Metabolic syndrome and diabetes mellitus in COPD. Eur Respir Soc Monograph. 2013;59:117-34.
48. Ignatova GL, Blinova EV, Antonov VN, et al. Analysis of the effect of vaccine prevention of pneumococcal infection in patients with chronic obstructive pulmonary disease in combination with diabetes mellitus. TerapevticheskiiArkhiv (Ter. Arkh.). 2019;91(11):49-54 (in Russian). DOI:10.26442/00403660.2019.11.000424
49. Drapkina OM, Briko NI, Kostinov MP, et al. Immunization of adults. Guidelines. Moscow: NMITs TPM, 2020. Available at: http://nasci.ru/?id=19860&download=1. Accessed: 11.02.22 (in Russian).
2. Wroe PC, Finkelstein JA, Ray GT, et al. Aging population and future burden of pneumococcal pneumonia in the United States. J Infect Dis. 2012;205(10):1589-92. DOI:10.1093/infdis/jis240
3. Заболеваемость взрослого населения России в 2019 году с диагнозом, установленным впервые в жизни. Статистические материалы. М., 2020 [Zabolevaemost' vzroslogo naseleniia Rossii v 2019 godu s diagnozom, ustanovlennym vpervye v zhizni. Statisticheskie materialy. Moscow, 2020 (in Russian)].
4. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquiredpneumonia among adults in Europe. Thorax. 2012;67:71-9. DOI:10.1136/thx.2009.129502
5. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39(11):1642-50. DOI:10.1086/425615
6. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122(2):130-41. DOI:10.3810/pgm.2010.03.2130
7. Ramirez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clin Infect Dis. 2017;65(11):1806-12. DOI:10.1093/cid/cix647
8. World Health Organization. The top 10 causes of death: 2019 updated. Available at: https://www.who.int/ru/news/item/09-12-2020-who-reveals-leading-causes-of-death-and-disability-world.... Accessed: 09.12.2020.
9. Metlay JP, Fine MJ. Testing strategies in the initial management of patents with community-acquired pneumonia. Ann Intern Med. 2003;138(2):109-18.
DOI:10.7326/0003-4819-138-2-200301210-00012
10. International Diabetes Federation. Diabetes Atlas 9th Ed. 2019. Available at: https://www.diabetesatlas.org/upload/resources/material/ Accessed: 09.12.2020.
11. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 10-й вып. М., 2021 [Algorithms of specialized medical care for patients with diabetes mellitus. Ed. II Dedov, MV Shestakova, A.Yu. Maiorov. 10th ed. Moscow, 2021 (in Russian)].
DOI:10.14341/DM12802
12. Дедов И.И., Калашникова М.Ф., Белоусов Д.Ю., и др.Фармакоэпидемиологические аспекты мониторинга здоровья пациентов с сахарным диабетом 2 типа: результаты Российского наблюдательного многоцентрового эпидемиологического исследования ФОРСАЙТ-СД 2. Сахарный диабет. 2016;19(6):443-56 [Dedov II, Kalashnikova MF, Belousov DY, et al. Assessing routine healthcare pattern for type 2 diabetes mellitus in Russia: the results of рharmacoepidemiological study (FORSIGHT-DM2). Diabetes Mellitus. 2016;19(6):443-56 (in Russian)]. DOI:10.14341/DM8146
13. Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infections disease hospitalization and outcome. Diabetologia. 2007;50(3):549-54. DOI:10.1007/s00125-006-0570-3
14. Kornum JB, Thomsen RW, Riis A, et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008;31(8):1541-5. DOI:10.2337/dc08-0138
15. Bruns AH, Oesterheert JJ, Cucciolillo MC, et al. Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia as compared with the general Dutch population. Clin Microbiol Infect. 2011;17(5):763-8. DOI:10.1111/j.1469-0691.2010.03296.x
16. Lepper HM, Ott S, Nuesch E, et al. German Community Acquired Pneumonia Competence Network. Serum glucose level for predicting death in patients admitted to hospital for community-acquired pneumonia: prospective cohort study. BMJ. 2012;344(5):3397. DOI:10.1136/bmj.e3397
17. Kondapally Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk cause-specific death. The emerging risk factors collaboration. N Engl J Med. 2011;364(9):829-41. DOI:10.1056/NEJMoa1008862
18. Жук Е.А. Изменения иммунологических параметров при диабетическом кетоацидозе. Актуальные проблемы современной эндокринологии: Материалы IV Всероссийского конгресса эндокринологов. СПб., 2001; с. 68 [Zhuk EA. Izmeneniia immunologicheskikh parametrov pri diabeticheskom ketoatsidoze. Aktual'nye problemy sovremennoi endokrinologii: Materialy IV Vserossiiskogo kongressa endokrinologov. Saint Petersburg, 2001; p. 68 (in Russian)].
19. Костинов М.П., Тарасова А.А. Вакцинопрофилактика пневмококковой инфекции и гриппа при аутоиммунных заболеваниях. Руководство для врачей. М.: МДВ, 2009 [Kostinov MP, Tarasova AA. Vaktsinoprofilaktika pnevmokokkovoi infektsii i grippa pri autoimmunnykh zabolevaniiakh. Rukovodstvo dlia vrachei. Moscow: MDV, 2009 (in Russian)].
20. Clement S, Braithwaite SS, Magel MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27(2):553-91. DOI:10.2337/diacare.27.2.553
21. Verrotti A, Loiacono G, Mohn A, et al. New in sights in diabetic autonomic neuropathy in children and adolescents. Eur J Endocrinol. 2009;161:811-8.
DOI:10.1530/EJE-09-0710
22. Лысенко Л.В. Диабетическая макро- и микроангиопатия легких. Арх. патогии. 1990;11:31-6 [Lysenko LV. Diabetic macro- and microangiopathy of the lungs. Arch. patologii. 1990;11:31-6 (in Russian)].
23. Колодова И.М., Лысенко Л.В., Салтыков Б.Б. Изменения в легких при сахарном диабете. Арх. патологии. 1982;7:35-40 [Kolodova IM, Lysenko LV, Saltykov B. Changes in the lungs in diabetes mellitus. Arch. patologii. 1982;7:35-40 (in Russian)].
24. Movahed MR, Hashemzadeh M, Jamal MM. The prevalence of pulmonary embolism and pulmonary hypertension in patients with type II diabetes mellitus. CHEST. 128(5):3568-71. DOI:10.1378/chest.128.5.3568
25. Zhang RH, Zhou JB, Cai YM, et al. Non-linear association between diabetes mellitus and pulmonary function: a population-based study. Respir Res. 2020;21(1):292. DOI:10.1186/s12931-020-01538-2
26. Lange P, Groth S, Kastrup J, et al. Diabetes mellitus, plasma glucose and lung function in a cross-sectional population study. Eur Resp. 1989;2:4-19.
27. Mancini M, Filippelli G, Seghieri, et al. Respiratory muscle function and hypoxic ventilatory control in patients with type I diabetes. Chest. 1999;115(6):1553-62. DOI:10.1378/chest.115.6.1553
28. Benbassat CA, Stern E, Kramer M, et al. Pulmonary function in patients with diabetes mellitus. Am J Med Sci. 2001;322(3):127-32. DOI:10.1097/00000441-200109000-00003
29. Boulbou MS, Gourgoulianis KI, Klisiaris VV, et al. Diabetes mellitus and lung function. Med Princ Pract. 2003;12(2):87-91. DOI:10.1159/000069118
30. Муминоров А.И., Шамирзоев Н.Х., Джаббаров Н.Д. Морфологические исследования слизистой оболочки носовой полости при сахарном диабете. Вестн. отоларингологии. 1980;4:39-42 [Muminorov AI, Shamirzoev NKh, Jabbarov ND. Morphological studies of the nasal mucosa in diabetes mellitus. Vestn. otolaryngologii. 1980;4:39-42 (in Russian)].
31. Yue W. Nasal mucocillary clearance in patients with diabetes mellitus. J Laryngol Otol. 1989;103(9):853-5. DOI:10.1017/s0022215100110291
32. Sachdeva A, Sachdeva O, Gualti S, еt al. Nasal mucocilliary clearance & mucus pH in patients with diabetes mellitus. Indian J Med Res. 1993;98:265-68.
33. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):ofu024. DOI:10.1093/ofid/ofu024
34. Иванчик Н.В., Чагарян А.Н., Сухорукова М.В., и др. Антибиотико-резистентность клинических штаммов Streptococcus pneumoniae в России: результаты многоцентрового эпидемиологического исследования «ПЕГАС 2014–2017». Клиническая микробиология и антимикробная химиотерапия. 2019;21(3):230-7 [Ivanchik NV, Chagaryan АN, Sukhorukova МV, et al. Antimicrobial resistance of clinical Streptococcus pneumoniae isolates in Russia: the results of multicenter epidemiological study “PEHASus 2014–2017”. Clinical Microbiology and Antimicrobial Chemotherapy. 2019;21(3):230-7 (in Russian)]. DOI:10.36488/cmac.2019.3.230-237
35. Белошитский Г.В., Королева И.С., Миронов К.О. Фенотипическая и генотипическая характеристика штаммов пневмококков, выделенных от больных пневмококковым менингитом. Клиническая микробиология и антимикробная химиотерапия. 2011;13(3):216-66
[Beloshitsky GV, Koroleva IS, Mironov KO. Phenotypic and genotypic characteristics of pneumococcal strains isolated from patients with pneumococcal meningitis. Clinical Microbiology and Antimicrobial Chemotherapy. 2011;13(3):216-66 (in Russian)].
36. Pollard AJ, Bijker EM. A guide to vaccinology: from basicprinciples to new developments. Nat Rev Immunol. 2021;21(2):83-100. DOI:10.1038/s41577-020-00479-7
37. Руководство по клинической иммунологии в респираторной медицине. Под ред М.П. Костинова, А.Г. Чучалина. М., 2018 [Rukovodstvo po klinicheskoi immunologii v respiratornoi meditsine. Pod red. MP Kostinova, AG Chuchalina. Moscow, 2018 (in Russian)].
38. Чучалин А.Г., Брико Н.И., Авдеев С.Н., и др. Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у взрослых. Пульмонология. 2019;29(1):19-34 [Chuchalin AG, Briko NI, Avdeev SN, et al. Federal Clinical Guidelines on Preventive Vaccination Against Pneumococcal infections in Adults. Pulmonologiya. 2019;29(1):19-34 (in Russian)]. DOI:10.18093/0869-0189-2019-29-1-19-34
39. Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60–64 years of age. Vaccine. 2014;32(20):2364-74. DOI:10.1016/j.vaccine.2014.02.002
40. Shiramoto M, Hanada R, Juergens C, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. Hum Vaccin Immunother. 2015;11(9):2198-206. DOI:10.1080/21645515.2015.1030550
41. Kuo CS, Lu CW, Chang YK, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly. Medicine (Baltimore). 2016;95(26):e4064. DOI:10.1097/MD.0000000000004064
42. McDonald HI, Thomas SL, Millett ER, et al. Do influenza and pneumococcal vaccines prevent community-acquired respiratory infections among older people with diabetes and does this vary by chronic kidney disease? A cohort study using electronic health record. BMJ Open Diabetes Res Care. 2017;5:e000332. DOI:10.1136/bmjdrc-2016-000332
43. Bonten MJ, Huijts SM, Bolkenbaas V, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-25. DOI:10.1056/NEJMoa1408544
44. Huijts SM, van Werkhoven CH, Bolkenbaas M, et al. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly. Vaccine. 2017;35(34):4444-9. DOI:10.1016/j.vaccine.2017.01.071
45. McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. Clin Infect Dis. 2018;67(10):1498-506. DOI:10.1093/cid/ciy312
46. Ehrlich SF, Quesenberry CP Jr, Van Den Eeden SK, et al. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care. 2010;33(1):55-60. DOI:10.2337/dc09-0880
47. Wells CE, Baker EH. Metabolic syndrome and diabetes mellitus in COPD. Eur Respir Soc Monograph. 2013;59:117-34.
48. Игнатова Г.Л., Блинова Е.В., Антонов В.Н., и др. Анализ влияния вакцинопрофилактики пневмококковой инфекции у пациентов с хронической обструктивной болезнью легких в сочетании с сахарным диабетом. Терапевтический архив. 2019;91(11):49-54 [Ignatova GL, Blinova EV, Antonov VN, et al. Analysis of the effect of vaccine prevention of pneumococcal infection in patients with chronic obstructive pulmonary disease in combination with diabetes mellitus. TerapevticheskiiArkhiv (Ter. Arkh.). 2019;91(11):49-54 (in Russian)]. DOI:10.26442/00403660.2019.11.000424
49. Драпкина О.М., Брико Н.И., Костинов М.П., и др. Иммунизация взрослых. Методические рекомендации. М.: ФГБУ «НМИЦ ТПМ» Минздрава России, 2020. Режима доступа: http://nasci.ru/?id=19860&download=1 Ссылка активна на 11.02.2022 [Drapkina OM, Briko NI, Kostinov MP, et al. Immunization of adults. Guidelines. Moscow: NMITs TPM, 2020. Available at: http://nasci.ru/?id=19860&download=1. Accessed: 11.02.22 (in Russian)].
________________________________________________
2. Wroe PC, Finkelstein JA, Ray GT, et al. Aging population and future burden of pneumococcal pneumonia in the United States. J Infect Dis. 2012;205(10):1589-92. DOI:10.1093/infdis/jis240
3. Zabolevaemost' vzroslogo naseleniia Rossii v 2019 godu s diagnozom, ustanovlennym vpervye v zhizni. Statisticheskie materialy. Moscow, 2020 (in Russian).
4. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquiredpneumonia among adults in Europe. Thorax. 2012;67:71-9. DOI:10.1136/thx.2009.129502
5. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39(11):1642-50. DOI:10.1086/425615
6. File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122(2):130-41. DOI:10.3810/pgm.2010.03.2130
7. Ramirez JA, Wiemken TL, Peyrani P, et al. Adults hospitalized with pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clin Infect Dis. 2017;65(11):1806-12. DOI:10.1093/cid/cix647
8. World Health Organization. The top 10 causes of death: 2019 updated. Available at: https://www.who.int/ru/news/item/09-12-2020-who-reveals-leading-causes-of-death-and-disability-world.... Accessed: 09.12.2020.
9. Metlay JP, Fine MJ. Testing strategies in the initial management of patents with community-acquired pneumonia. Ann Intern Med. 2003;138(2):109-18.
DOI:10.7326/0003-4819-138-2-200301210-00012
10. International Diabetes Federation. Diabetes Atlas 9th Ed. 2019. Available at: https://www.diabetesatlas.org/upload/resources/material/ Accessed: 09.12.2020.
11. Algorithms of specialized medical care for patients with diabetes mellitus. Ed. II Dedov, MV Shestakova, A.Yu. Maiorov. 10th ed. Moscow, 2021 (in Russian).
DOI:10.14341/DM12802
12. Dedov II, Kalashnikova MF, Belousov DY, et al. Assessing routine healthcare pattern for type 2 diabetes mellitus in Russia: the results of рharmacoepidemiological study (FORSIGHT-DM2). Diabetes Mellitus. 2016;19(6):443-56 (in Russian). DOI:10.14341/DM8146
13. Benfield T, Jensen JS, Nordestgaard BG. Influence of diabetes and hyperglycaemia on infections disease hospitalization and outcome. Diabetologia. 2007;50(3):549-54. DOI:10.1007/s00125-006-0570-3
14. Kornum JB, Thomsen RW, Riis A, et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008;31(8):1541-5. DOI:10.2337/dc08-0138
15. Bruns AH, Oesterheert JJ, Cucciolillo MC, et al. Cause-specific long-term mortality rates in patients recovered from community-acquired pneumonia as compared with the general Dutch population. Clin Microbiol Infect. 2011;17(5):763-8. DOI:10.1111/j.1469-0691.2010.03296.x
16. Lepper HM, Ott S, Nuesch E, et al. German Community Acquired Pneumonia Competence Network. Serum glucose level for predicting death in patients admitted to hospital for community-acquired pneumonia: prospective cohort study. BMJ. 2012;344(5):3397. DOI:10.1136/bmj.e3397
17. Kondapally Seshasai SR, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk cause-specific death. The emerging risk factors collaboration. N Engl J Med. 2011;364(9):829-41. DOI:10.1056/NEJMoa1008862
18. Zhuk EA. Izmeneniia immunologicheskikh parametrov pri diabeticheskom ketoatsidoze. Aktual'nye problemy sovremennoi endokrinologii: Materialy IV Vserossiiskogo kongressa endokrinologov. Saint Petersburg, 2001; p. 68 (in Russian).
19. Kostinov MP, Tarasova AA. Vaktsinoprofilaktika pnevmokokkovoi infektsii i grippa pri autoimmunnykh zabolevaniiakh. Rukovodstvo dlia vrachei. Moscow: MDV, 2009 (in Russian).
20. Clement S, Braithwaite SS, Magel MF, et al. Management of diabetes and hyperglycemia in hospitals. Diabetes Care. 2004;27(2):553-91. DOI:10.2337/diacare.27.2.553
21. Verrotti A, Loiacono G, Mohn A, et al. New in sights in diabetic autonomic neuropathy in children and adolescents. Eur J Endocrinol. 2009;161:811-8.
DOI:10.1530/EJE-09-0710
22. Lysenko LV. Diabetic macro- and microangiopathy of the lungs. Arch. patologii. 1990;11:31-6 (in Russian).
23. Kolodova IM, Lysenko LV, Saltykov B. Changes in the lungs in diabetes mellitus. Arch. patologii. 1982;7:35-40 (in Russian).
24. Movahed MR, Hashemzadeh M, Jamal MM. The prevalence of pulmonary embolism and pulmonary hypertension in patients with type II diabetes mellitus. CHEST. 128(5):3568-71. DOI:10.1378/chest.128.5.3568
25. Zhang RH, Zhou JB, Cai YM, et al. Non-linear association between diabetes mellitus and pulmonary function: a population-based study. Respir Res. 2020;21(1):292. DOI:10.1186/s12931-020-01538-2
26. Lange P, Groth S, Kastrup J, et al. Diabetes mellitus, plasma glucose and lung function in a cross-sectional population study. Eur Resp. 1989;2:4-19.
27. Mancini M, Filippelli G, Seghieri, et al. Respiratory muscle function and hypoxic ventilatory control in patients with type I diabetes. Chest. 1999;115(6):1553-62. DOI:10.1378/chest.115.6.1553
28. Benbassat CA, Stern E, Kramer M, et al. Pulmonary function in patients with diabetes mellitus. Am J Med Sci. 2001;322(3):127-32. DOI:10.1097/00000441-200109000-00003
29. Boulbou MS, Gourgoulianis KI, Klisiaris VV, et al. Diabetes mellitus and lung function. Med Princ Pract. 2003;12(2):87-91. DOI:10.1159/000069118
30. Muminorov AI, Shamirzoev NKh, Jabbarov ND. Morphological studies of the nasal mucosa in diabetes mellitus. Vestn. otolaryngologii. 1980;4:39-42 (in Russian).
31. Yue W. Nasal mucocillary clearance in patients with diabetes mellitus. J Laryngol Otol. 1989;103(9):853-5. DOI:10.1017/s0022215100110291
32. Sachdeva A, Sachdeva O, Gualti S, еt al. Nasal mucocilliary clearance & mucus pH in patients with diabetes mellitus. Indian J Med Res. 1993;98:265-68.
33. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):ofu024. DOI:10.1093/ofid/ofu024
34. Ivanchik NV, Chagaryan АN, Sukhorukova МV, et al. Antimicrobial resistance of clinical Streptococcus pneumoniae isolates in Russia: the results of multicenter epidemiological study “PEHASus 2014–2017”. Clinical Microbiology and Antimicrobial Chemotherapy. 2019;21(3):230-7 (in Russian). DOI:10.36488/cmac.2019.3.230-237
35. Beloshitsky GV, Koroleva IS, Mironov KO. Phenotypic and genotypic characteristics of pneumococcal strains isolated from patients with pneumococcal meningitis. Clinical Microbiology and Antimicrobial Chemotherapy. 2011;13(3):216-66 (in Russian).
36. Pollard AJ, Bijker EM. A guide to vaccinology: from basicprinciples to new developments. Nat Rev Immunol. 2021;21(2):83-100. DOI:10.1038/s41577-020-00479-7
37. Rukovodstvo po klinicheskoi immunologii v respiratornoi meditsine. Pod red. MP Kostinova, AG Chuchalina. Moscow, 2018 (in Russian).
38. Chuchalin AG, Briko NI, Avdeev SN, et al. Federal Clinical Guidelines on Preventive Vaccination Against Pneumococcal infections in Adults. Pulmonologiya. 2019;29(1):19-34 (in Russian). DOI:10.18093/0869-0189-2019-29-1-19-34
39. Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60–64 years of age. Vaccine. 2014;32(20):2364-74. DOI:10.1016/j.vaccine.2014.02.002
40. Shiramoto M, Hanada R, Juergens C, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults. Hum Vaccin Immunother. 2015;11(9):2198-206. DOI:10.1080/21645515.2015.1030550
41. Kuo CS, Lu CW, Chang YK, et al. Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly. Medicine (Baltimore). 2016;95(26):e4064. DOI:10.1097/MD.0000000000004064
42. McDonald HI, Thomas SL, Millett ER, et al. Do influenza and pneumococcal vaccines prevent community-acquired respiratory infections among older people with diabetes and does this vary by chronic kidney disease? A cohort study using electronic health record. BMJ Open Diabetes Res Care. 2017;5:e000332. DOI:10.1136/bmjdrc-2016-000332
43. Bonten MJ, Huijts SM, Bolkenbaas V, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-25. DOI:10.1056/NEJMoa1408544
44. Huijts SM, van Werkhoven CH, Bolkenbaas M, et al. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly. Vaccine. 2017;35(34):4444-9. DOI:10.1016/j.vaccine.2017.01.071
45. McLaughlin JM, Jiang Q, Isturiz RE, et al. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design. Clin Infect Dis. 2018;67(10):1498-506. DOI:10.1093/cid/ciy312
46. Ehrlich SF, Quesenberry CP Jr, Van Den Eeden SK, et al. Patients diagnosed with diabetes are at increased risk for asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, and pneumonia but not lung cancer. Diabetes Care. 2010;33(1):55-60. DOI:10.2337/dc09-0880
47. Wells CE, Baker EH. Metabolic syndrome and diabetes mellitus in COPD. Eur Respir Soc Monograph. 2013;59:117-34.
48. Ignatova GL, Blinova EV, Antonov VN, et al. Analysis of the effect of vaccine prevention of pneumococcal infection in patients with chronic obstructive pulmonary disease in combination with diabetes mellitus. TerapevticheskiiArkhiv (Ter. Arkh.). 2019;91(11):49-54 (in Russian). DOI:10.26442/00403660.2019.11.000424
49. Drapkina OM, Briko NI, Kostinov MP, et al. Immunization of adults. Guidelines. Moscow: NMITs TPM, 2020. Available at: http://nasci.ru/?id=19860&download=1. Accessed: 11.02.22 (in Russian).
Авторы
Г.Л. Игнатова1, Е.В. Блинова1, С.В. Струч*2, М.А. Сырочкина3
1 ФГБОУ ВО «Южно-Уральский государственный медицинский университет», Челябинск, Россия;
2 ООО «Пфайзер Инновации», Москва, Россия;
3 «Пфайзер», Офаким, Израиль
*sveta.struch@yandex.ru
1 South Ural Sate Medical University, Chelyabinsk, Russia;
2 Medical Department Vaccines, Pfizer, Moscow, Russia;
3 Medical Department Vaccines, Pfizer, Ofaqim, Israel
*sveta.struch@yandex.ru
1 ФГБОУ ВО «Южно-Уральский государственный медицинский университет», Челябинск, Россия;
2 ООО «Пфайзер Инновации», Москва, Россия;
3 «Пфайзер», Офаким, Израиль
*sveta.struch@yandex.ru
________________________________________________
1 South Ural Sate Medical University, Chelyabinsk, Russia;
2 Medical Department Vaccines, Pfizer, Moscow, Russia;
3 Medical Department Vaccines, Pfizer, Ofaqim, Israel
*sveta.struch@yandex.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.